This Phase 2 randomized clinical trial was published in the journal Frontiers in Oncology in May 2021, and focused on the tolerability and side effects of cannabis extracts in patients with fast-growing tumors of the glial cells in the brain and spinal cord.
The study found that over a 12 week period, a 1:1 THC:CBD ratio product was more effective at improving quality of life scores than a 4:1 THC:CBD ratio product. The patients took a single dose at night and and reported significantly improved sleep, functional wellbeing, and quality of life. No serious adverse events occurred, and there was no significant reduction in disease status.
The average single daily doses used were about 10mg THC & 10mg CBD (1:1) OR 27mg THC & 7mg CBD (4:1). However, dosing ranged above and below these numbers based on individual patient tolerances.
The published report is here.